title: Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia.
authors.forename: Tae Sung
authors.initials: TS
authors.lastname: Park
authors.forename: June-Won
authors.initials: JW
authors.lastname: Cheong
authors.forename: Soo Jeong
authors.initials: SJ
authors.lastname: Kim
authors.forename: Kyung Woo
authors.initials: KW
authors.lastname: Lee
authors.forename: Jaewoo
authors.initials: J
authors.lastname: Song
authors.forename: Kyung-A
authors.initials: KA
authors.lastname: Lee
authors.forename: Borum
authors.initials: B
authors.lastname: Suh
authors.forename: Sungwook
authors.initials: S
authors.lastname: Song
authors.forename: Jong Rak
authors.initials: JR
authors.lastname: Choi
mesh_terms: D019943:Amino Acid Substitution / Q000235:genetics; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D001549:Benzamides; D002888:Chromosomes, Human, Pair 19; D002893:Chromosomes, Human, Pair 3; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D018698:Glutamic Acid / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D020125:Mutation, Missense; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D014178:Translocation, Genetic; D014314:Trisomy; D014633:Valine / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D018698:Glutamic Acid; D000068877:Imatinib Mesylate; D014633:Valine